Calcium channel blockers and dementia
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Degenerative dementia is mainly caused by A lzheimer's disease and/or cerebrovascular abnormalities. Disturbance of the intracellular calcium homeostasis is central to the pathophysiology of neurodegeneration. In A lzheimer's disease, enhanced calcium load may be brought about by extracellular accumulation of amyloid‐β. Recent studies suggest that soluble forms facilitate influx through calcium‐conducting ion channels in the plasma membrane, leading to excitotoxic neurodegeneration. Calcium channel blockade attenuates amyloid‐β‐induced neuronal decline in vitro and is neuroprotective in animal models. Vascular dementia, on the other hand, is caused by cerebral hypoperfusion and may benefit from calcium channel blockade due to relaxation of the cerebral vasculature. Several calcium channel blockers have been tested in clinical trials of dementia and the outcome is heterogeneous. Nimodipine as well as nilvadipine prevent cognitive decline in some trials, whereas other calcium channel blockers failed. In trials with a positive outcome, BP reduction did not seem to play a role in preventing dementia, indicating a direct protecting effect on neurons. An optimization of calcium channel blockers for the treatment of dementia may involve an increase of selectivity for presynaptic calcium channels and an improvement of the affinity to the inactivated state. Novel low molecular weight compounds suitable for proof‐of‐concept studies are now available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“According to the amyloid cascade hypothesis, overproduction of the hydrophobic peptide Aβ 1–42 is the basis for AD pathology (Hardy and Higgins, 1992).”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 2×
“These preparations were tested in vitro and in animal models, and the results lead to the generally accepted view that Aβ oligomers specifically disturb synaptic function (Walsh and Selkoe, 2007).”
ResultShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“Such down-regulation of the NMDA receptor current also reduces calcium influx into the cell, which was demonstrated in neurons by Shankar et al. (2007).”
BackgroundForette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 1×
“While nifedipine, diltiazem and verapamil showed no efficacy, nitrendipine was preventive in hypertensive patients (Forette et al., 1998; 2002).”
Background(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 1×
“While nifedipine, diltiazem and verapamil showed no efficacy, nitrendipine was preventive in hypertensive patients (Forette et al., 1998; 2002).”
BackgroundEarly-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03407.x · Cited by 559
Self-citationAnekonda, T. S., Quinn, J. F., Harris, C., Frahler, K., Wadsworth, T. L., & Woltjer, R. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.020 · Cited by 155 · cited 1×
“Other calcium antagonists (verapamil, diltiazem and isradipine) all dose dependently protected Aβ-induced cellular degeneration in cultured cells (Anekonda et al., 2011; Copenhaver et al., 2011), strengthening the conclusion that L-type channels may mediate the toxic effect.”
BackgroundCalcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114 · cited 1×
“It has recently been shown that calcium channel blockers such as nilvadipine and nitrendipine may also reduce the accumulation of Aβ in the brain of APP-overexpressing mice (Paris et al., 2011).”
Background
Cited by
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration
Verma, M., Lizama, B. N., & Chu, C. T. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-021-00278-7 · Cited by 451
Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
The dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
Hussain, S., Singh, A., Rahman, S. O., Habib, A., & Najmi, A. K. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.02.027 · Cited by 52
Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy
Chakraborty, A., Kamermans, A., van het Hof, B., Castricum, K., Aanhane, E., van Horssen, J., Thijssen, V. L., Scheltens, P., Teunissen, C. E., Fontijn, R. D., et al. (2018) · Brain · doi:10.1093/brain/awy274 · Cited by 45
Metadata
- Authors
- Nimmrich, V, & Eckert, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-06-21
- Volume
- 169
- Issue
- 6
- Pages
- 1203-1210
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1529339318
- Cited by
- 155
- References
- 16
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.